Main Article Content
Background. The purpose of the study is to establish the efficiency and safety of the use of ipidacrine (Neuromidin) in patients with type 2 diabetes mellitus complicated by distal symmetric polyneuropathy. Materials and methods. One hundred ten patients with distal symmetric polyneuropathy were examined. Selected patients were divided into 2 groups: group I (n = 24) — persons receiving basic treatment; group II (n = 50) — patients who received Neuromidin, in the form of intramuscular injections of 5 mg 2 times a day for 10 days, then orally 20 mg 3 times a day for 20 days. All patients underwent neurological examination using Neuropathy Symptom Score, Neuropathy Disability Score, electroneuromyographic (ENMG) testing of the peripheral nerves of the lower extremities. In order to establish the peculiarities of cognitive functions, Mini-Mental State Examination was used. Also, the rates of anxiety and depression in the dynamics of treatment were assessed. Results. In the group of people who received Neuromidin on the background of basic treatment, there was a significant improvement in the subjective and objective symptoms. The manifestations of axonopathy and myelinopathy according to the results of ENMG testing of peripheral nerves were believed to decrease in the group of patients taking Neuromidin against the background of basic treatment. Also, a statistically significant improvement of cognitive functions, reduction of anxiety and depression manifestations was established with the administration of Neuromidin. Conclusions. The application of Neuromidin on the background of basic therapy in patients with distal symmetric polyneuropathy improves the processes of regeneration and reinnervation of the peripheral nerves of the lower extremities and improves motor fibers conduction according to the ENMG parameters, has a positive effect on the clinical course of the disease, as well as improves cognitive function, reduces manifestations of anxiety and depression.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Lomova-Williams L, Mallipedhi A, MacIver C, et al. Research letter in relation to paper by Bongaerts et al., a clinical screening score for diabetic polyneuropathy: KORA F4 and AusDiab studies. J Diabetes Complications. 2015 Mar;29(2):318-9. doi: 10.1016/j.jdiacomp.2014.11.016.
Oros MM, Smolanka VI, Yathynyn RYu, Savytska NO. Paresis in neuropathy and radiculopathy: treatment tactics. International neurological journal. 2017;(94):53-55. doi: 10.22141/2224-07188.8.131.527.120701. (in Ukrainian).
Pashkovska NV, Pashkovsky VM. Dynamics of indicators of cognitive functions and emotional and personal reactions in patients with diabetic encephalopathy under the influence of treatment with neuromidin. Ukrainian Neurological Journal. 2012;(24):67-72. (in Ukrainian).